You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The single-cell genomics firm's agreements with multiple companies will cover Japan, South Korea, Taiwan, Australia, and New Zealand.
Albertsons said that the planned national rollout follows the rapid adoption of the test kit during a pilot launch in three market areas.
Golden Gateway, which operates throughout the Asia Pacific region, will exclusively distribute UST's linked read library preparation kit in Australia.
IsoPlexis' single-cell proteomics products will be made available to researchers in these countries through Medquest.
News items for the week of August 10, 2020.
HTG will work directly with biopharma customers to build companion diagnostic development programs, with potential tests developed using either a Thermo Fisher Scientific or Illumina platform.
Fluidigm's Helios mass cytometer and Hyperion imaging system will be bundled with De Novo's FCS Express 7 Flow software for suspension data analysis.
The test, which has Emergency Use Authorization from the US Food and Drug Administration, is designed to detect the SARS-CoV-2 ORF1ab, N, and E genes.
The partnership will provide Chinese customers access to the company's IsoLight platform, which enables multiplexed immunoassays at the single-cell level.
The agreement is Oncocyte's second distribution deal this year following an agreement with Core Diagnostics to sell the test in Africa and the Middle East.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.